We are live on ! Find out more
ZBIO

Zenas BioPharma
ZBIO

139 hedge funds and large institutions have $1.1B invested in Zenas BioPharma in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 57 increasing their positions, 17 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

235% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 17

89% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 27

29% more call options, than puts

Call options by funds: $3.48M | Put options by funds: $2.71M

19.13% more ownership

Funds ownership: 77.43% → 96.56% (+19%)

18% more funds holding

Funds holding: 118 → 139 (+21)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

27% less capital invested

Capital invested by funds: $1.5B → $1.1B (-$407M)

Holders
139
Holders Change
+21
Holders Change %
+17.8%
% of All Funds
1.71%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.09%
New
51
Increased
57
Reduced
17
Closed
27
Calls
$3.48M
Puts
$2.71M
Net Calls
+$774K
Net Calls Change
-$2.57M

Top Buyers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
+$54.6M
2
PCH
Polar Capital Holdings
United Kingdom
+$33.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$30.9M
4
SCM
Silverarc Capital Management
Massachusetts
+$25.5M
5
State Street
State Street
Massachusetts
+$23.2M

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$52.6M
2
VC
Vivo Capital
California
-$31M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.21M
4
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB)
Sweden
-$5.95M
5
EP
Eversept Partners
New York
-$4.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
51
Exome Asset Management
New York
$1.58M +$1.81M +80,730 New
Voloridge Investment Management
52
Voloridge Investment Management
Florida
$1.51M -$1.26M -55,946 -42%
BC
53
Birchview Capital
Vermont
$1.37M +$1.57M +70,000 New
N
54
Nuveen
North Carolina
$1.32M +$380K +16,920 +33%
Citadel Advisors
55
Citadel Advisors
Florida
$1.31M +$952K +42,411 +173%
Bank of New York Mellon
56
Bank of New York Mellon
New York
$1.19M +$203K +9,062 +17%
JF
57
Jump Financial
Illinois
$1.17M +$1.35M +60,001 New
AQR Capital Management
58
AQR Capital Management
Connecticut
$996K -$612K -27,249 -35%
Rafferty Asset Management
59
Rafferty Asset Management
New York
$942K +$1.08M +48,169 New
AA
60
ALPS Advisors
Colorado
$854K -$8.6K -383 -0.9%
Squarepoint
61
Squarepoint
New York
$838K +$614K +27,333 +176%
DCM
62
DAFNA Capital Management
California
$831K +$954K +42,500 New
BGM
63
Burkehill Global Management
New York
$782K +$898K +40,000 New
JGC
64
J. Goldman & Co
New York
$719K +$826K +36,797 New
Swiss National Bank
65
Swiss National Bank
Switzerland
$618K – – –
Schroder Investment Management Group
66
Schroder Investment Management Group
United Kingdom
$614K -$380K -16,939 -33%
VCM
67
Voleon Capital Management
California
$579K +$436K +19,425 +191%
Barclays
68
Barclays
United Kingdom
$579K -$107K -4,767 -14%
Jacobs Levy Equity Management
69
Jacobs Levy Equity Management
New Jersey
$538K +$618K +27,532 New
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$524K +$109K +4,867 +22%
HF
71
HRT Financial
New York
$503K +$578K +25,749 New
JP Morgan Chase
72
JP Morgan Chase
New York
$458K +$75.9K +3,383 +16%
PA
73
Profund Advisors
Maryland
$419K +$481K +21,416 New
QCM
74
Quantinno Capital Management
New York
$413K +$474K +21,126 New
VGA
75
Vanguard Global Advisers
Pennsylvania
$407K +$468K +20,840 New
1 2
3
4 5

ZBIO Hedge Fund Activity: Q1 2026 in Review

139 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q1 2026, worth a combined $1.1B — down 27% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ZBIO positions and 27 closed out — a net gain of 24 holders — while 57 added to existing stakes and 17 trimmed.

The largest buyer was Capital International Investors, opening a new position worth an estimated $54.6M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $52.6M sold.

  • 139 institutional investors held Zenas BioPharma (ZBIO) as of Q1 2026, up from 118 in Q4 2025.
  • Funds reported $1.1B of Zenas BioPharma stock for Q1 2026, down 27% quarter-over-quarter.
  • 51 funds opened new Zenas BioPharma positions in Q1 2026 and 27 closed out, a net change of +24 holders.
  • The largest Zenas BioPharma buyer in Q1 2026 was Capital International Investors, an estimated $54.6M added.
  • The largest Zenas BioPharma seller in Q1 2026 was Novo Holdings A/S, an estimated $52.6M sold.

Based on aggregated 13F filings for Q1 2026.